BRAF and cancer: In another meta-analysis of eight studies (351 BRAF-mt patients), excluding the NORDIC and FIRE-3 trials, the authors reported a non significant interaction between anti-EGFR treatment and BRAF mutations, concluding that the data were insufficient to justify the exclusion of anti-EGFR agents for the treatment of BRAF-mt cancer (25).